Invion (IVX) Price & Analysis

Compare

4 Followers

IVX Stock Chart & Stats

AU$0.08

AU$0.00(0.00%)

At close: Jan 09 4:00 PM EST

AU$0.08

AU$0.00(0.00%)

Day’s Range― - ―

52-Week RangeAU$0.08 - AU$0.20

Previous CloseN/A

Volume36.17K

Average Volume (3M)97.01K

Market Cap

AU$7.37M

Enterprise ValueAU$8.15M

Total Cash (Recent Filing)AU$137.54K

Total Debt (Recent Filing)AU$627.68K

Price to Earnings (P/E)―

Beta0.73

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding96,965,320

10 Day Avg. Volume121,261

30 Day Avg. Volume97,006

Financial Highlights & Ratios

PEG Ratio-0.02

Price to Book (P/B)0.96

Price to Sales (P/S)0.00

P/FCF Ratio-2.67

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Low Leverage / No Reported DebtA clean capital structure with no reported debt materially reduces fixed interest obligations and insolvency risk for a pre-revenue biotech. This preserves financial flexibility to pursue R&D and licensing discussions, lengthening runway compared with highly leveraged peers.

Proprietary Platform (Photosoft)Owning a differentiated photodynamic therapy platform creates a scalable, repeatable R&D model: a single technology can spawn multiple candidates and indications. That structural advantage supports partnership and licensing opportunities and underpins long-term value if clinical translation succeeds.

Lean Operating StructureA very small headcount implies lower fixed payroll and overhead, which helps conserve cash between financings. For an early-stage biopharma focused on preclinical work, a lean team can extend runway and enable concentrated use of capital on key experiments or milestone-driven partnerships.

Bears Say

Zero Revenue And Widening LossesThe company has no product revenue and losses have increased materially, reflecting that R&D and operating costs far outstrip any income. Over the medium term, persistent negative earnings erode equity cushions and make sustained progress dependent on external financing or milestone-based deals.

Significant Cash BurnConsistent negative operating cash flow demonstrates ongoing reliance on cash injections to fund R&D and operations. This structural cash burn increases dilution or refinancing risk, constrains the timing of clinical programs, and pressures management to secure funding before key milestones.

Shrinking Equity And Asset BaseMaterial declines in equity and total assets indicate value erosion from cumulative losses and cash depletion. A thinner balance sheet limits strategic options (partnerships, non-dilutive financing) and reduces the buffer to absorb setbacks, making long-term program advancement more dependent on near-term funding events.

Invion News

Invion Issues New Unquoted Options Under Employee Incentive Scheme

The latest announcement is out from Invion ( ($AU:IVX) ). Invion Limited has notified the market of the...

2d ago

Invion Issues New Shares as It Explores Expansion of Cancer Therapy Program

Invion ( ($AU:IVX) ) has shared an announcement. Invion Limited has issued 11,318,060 fully paid ordinary shares following...

9d ago

Invion Seeks ASX Quotation for 11.3 Million New Shares

The latest update is out from Invion ( ($AU:IVX) ). Invion Limited has applied to the Australian Securities...

9d ago

Invion Raises Capital via Convertible Notes to Accelerate Cancer Programs

Invion ( ($AU:IVX) ) has issued an update. Invion has issued 578,118 unsecured convertible notes under Tranche 1...

9d ago

Invion Issues Unquoted Convertible Notes to Bolster Funding Strategy

Invion ( ($AU:IVX) ) just unveiled an update. Invion Limited has notified the market of the issue of...

9d ago

Invion Loss Widens as Auditors Flag Going-Concern Risk

Invion ( ($AU:IVX) ) has shared an update. Invion Limited has reported a sharp deterioration in its financial...

15d ago

Invion Secures Global Photosoft Rights and Non-Dilutive Funding as Cancer Programs Advance

Invion ( ($AU:IVX) ) has provided an update. Invion reported a cash balance of A$138,000 at 31 December...

1M ago

Invion Plans Convertible Note Placement to Raise Capital

Invion ( ($AU:IVX) ) has issued an update. Invion Limited has lodged a notice with the ASX outlining...

1M ago

Invion Raises $1.3m in CEO-Backed Convertible Note to Accelerate Cancer Trials

Invion ( ($AU:IVX) ) has shared an update. Invion has secured commitments to raise about $1.3 million through...

1M ago

Invion Shares Halted on ASX Ahead of Capital Raising Announcement

The latest update is out from Invion ( ($AU:IVX) ). Invion Limited has requested and been granted a...

1M ago

IVX FAQ

What was Invion’s price range in the past 12 months?

Invion lowest share price was AU$0.07 and its highest was AU$0.20 in the past 12 months.

What is Invion’s market cap?

Invion’s market cap is AU$7.37M.

When is Invion’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Invion’s earnings last quarter?

Currently, no data Available

Is Invion overvalued?

According to Wall Street analysts Invion’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Invion pay dividends?

Invion does not currently pay dividends.

What is Invion’s EPS estimate?

Invion’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Invion have?

Invion has 96,965,320 shares outstanding.

What happened to Invion’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Invion?

Currently, no hedge funds are holding shares in AU:IVX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Invion Stock Smart Score

Underperform

Fundamentals

Return on Equity

-74.92%

Trailing 12-Months

Asset Growth

-39.74%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Invion

Invion (IVX) is a biotechnology company focused on the research, development, and commercialization of Photodynamic Therapy (PDT) for the treatment of various cancers. Operating primarily in the healthcare and pharmaceutical sectors, Invion is dedicated to advancing its novel technologies to offer innovative treatment solutions that can improve patient outcomes. The company's core products include its proprietary PDT compounds and related systems that leverage light-activated processes to target and destroy cancer cells.